Retrezin 10 mg (Tablet)
Unit Price: ৳ 2.00 (100's pack: ৳ 200.00)
Medicine Details
| Category | Details |
|---|---|
| Generic | Cetirizine hydrochloride |
| Company | Rn pharmaceuticals |
Indications
- Relief of symptoms associated with seasonal & perennial allergic rhinitis
- Treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria
- Treatment of allergen induced asthma
Pharmacology
- Potent H1 receptor antagonist
- No significant anticholinergic and antiserotonic effects
- Inhibits histamine-mediated early phase of allergic reaction
- Reduces migration of inflammatory cells
- Reduces release of mediators associated with late phase of allergic reaction
- Peak plasma concentrations of 257 mcg/L within one hour
- Plasma half-life of approximately 11 hours
Dosage & Administration
- Adult dosage: 1 tablet or 2 teaspoonfuls daily
- Children 6 years and older dosage: 1 tablet or 2 teaspoonfuls daily
- Children 2-6 years dosage: 1 teaspoonful once daily or 1/2 teaspoonful twice daily
- Children 6 months to 2 years dosage: 1/2 teaspoonful once daily
- Recommended intravenous dosage for adults and adolescents 12 years of age and older: 10 mg
- Recommended intravenous dosage for children 6 to 11 years of age: 5 mg or 10 mg
- Recommended intravenous dosage for children 6 months to 5 years of age: 2.5 mg
Interaction
- No clinically significant drug interactions with Theophylline
- No clinically significant drug interactions with Azithromycin
- No clinically significant drug interactions with Pseudoephedrine
- No clinically significant drug interactions with Ketoconazole
- No clinically significant drug interactions with Erythromycin
Contraindications
- History of hypersensitivity to Cetirizine or hydroxyzine
Side Effects
- Somnolence
Pregnancy & Lactation
- US FDA Pregnancy Category B
- Caution when administered to a nursing woman
Precautions & Warnings
- Caution when driving a car or operating heavy machinery
Use in Special Populations
- Total body clearance reduced and AUC and half-life increased in patients with mild to moderate hepatic and renal impairment
- Plasma levels unaffected by hemodialysis
- Safety demonstrated in pediatric patients aged 6 months to 5 years
- Clearance reduced in elderly patients in proportion to decrease in creatinine clearance
Therapeutic Class
- Sedating Anti-histamine
Storage Conditions
- Keep in a dry place away from light and heat
- Keep out of the reach of children